Search Results

You are looking at 1 - 10 of 53 items for :

Clear All
Open access

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society

factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate

Open access

Urszula Smyczyńska, Joanna Smyczyńska, Maciej Hilczer, Renata Stawerska, Ryszard Tadeusiewicz and Andrzej Lewiński

), in some of them also concentrations of IGF-I ( 7 , 8 , 9 , 13 ) and IGFBP-3 ( 7 , 9 ) have been processed. The most frequently used method of deriving models of GH therapy outcomes has been multiple linear regression (MLR) ( 6 , 7 , 10 , 11

Open access

M Krause, H Frederiksen, K Sundberg, F S Jørgensen, L N Jensen, P Nørgaard, C Jørgensen, P Ertberg, J H Petersen, U Feldt-Rasmussen, A Juul, K T Drzewiecki, N E Skakkebaek and A M Andersson

factor I (IGF-I) and its major binding protein: insulin-like growth factor-binding protein-3 (IGFBP3). IGF-I and IGFBP3 were both measured by a chemiluminescence immunoassay on the IDS-iSYS automated platform (Immuno Diagnostic Systems, IDS) at the

Open access

Werner F Blum, Abdullah Alherbish, Afaf Alsagheir, Ahmed El Awwa, Walid Kaplan, Ekaterina Koledova and Martin O Savage

Introduction The growth hormone (GH)–insulin-like growth factor (IGF)-I axis is the principle endocrine system regulating linear growth in children ( 1 ). Linked to the nutritional status of the individual, GH is a potent stimulator of IGF-I

Open access

Monika Bilic, Huma Qamar, Akpevwe Onoyovwi, Jill Korsiak, Eszter Papp, Abdullah Al Mahmud, Rosanna Weksberg, Alison D Gernand, Jennifer Harrington and Daniel E Roth

improve growth-related outcomes. The insulin-like growth factor (IGF) axis includes several signal and binding proteins, many of which are under the regulation of growth hormone. IGF-I is the primary regulator of fetal growth, and its circulating

Open access

Alessandro Ciresi, Stefano Radellini, Valentina Guarnotta, Maria Grazia Mineo and Carla Giordano

one of the most influential regulators of growth hormone (GH) secretion and action, with different mechanisms ( 2 ). Androgens and estrogens exert opposite endocrine-mediated effects on insulin-like growth factor (IGF)-I production and metabolic

Open access

Juliane Léger, Anne Fjellestad-Paulsen, Anne Bargiacchi, Catherine Doyen, Emmanuel Ecosse, Jean-Claude Carel and Marie-France Le Heuzey

involving the growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis, thyroid function, hypercortisolemia, hypogonadotropic hypogonadism and the levels of several adipokines and gut peptides, such as ghrelin and peptide YY ( 2 ). The

Open access

Elena Valassi, Natalia García-Giralt, Jorge Malouf, Iris Crespo, Jaume Llauger, Adolfo Díez-Pérez and Susan M Webb

secondary hypogonadism. Because all of them were on stable testosterone replacement for more than 1 year, they were considered eugonadal. Nine women had regular menses and seven were postmenopausal. None of the patients had GH deficiency, diagnosed when IGF-I

Open access

Ananda A Santana-Ribeiro, Giulliani A Moreira-Brasileiro, Manuel H Aguiar-Oliveira, Roberto Salvatori, Vitor O Carvalho, Claudia K Alvim-Pereira, Carlos R Araújo-Daniel, Júlia G Reis-Costa, Alana L Andrade-Guimarães, Alécia A Oliveira-Santos, Edgar R Vieira and Miburge B Gois-Junior

, OMIM n. 612781), resulting in low serum GH and IGF-I throughout their life ( 12 ). Although these individuals are severely short, with reduced lean body mass and increased fat percentage, they perform vigorous daily physical activities such as pottery

Open access

Robert Rapaport, Peter A Lee, Judith L Ross, Paul Saenger, Vlady Ostrow and Giuseppe Piccoli

(eg, HSDS, age, insulin-like growth factor 1 (IGF-I) SDS) on changes in HSDS in response to GH therapy over time ( 12 , 13 ). The analysis described here evaluated growth outcomes (HSDS, IGF-I SDS and BMI SDS), bone age per chronological age (BA